Aldeyra Therapeu (ALDX)

Apr 4, 2025, 10:00 AM EDT - 6 hours ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out

Apr 4, 2025, 7:33 AM EDT - 9 hours ago

ALDX NOTIFICATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations after 75% Stock Drop; Investors with Losses are Notified to Contact BFA Law

Apr 3, 2025, 5:30 PM EDT - 23 hours ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out

Apr 3, 2025, 12:34 PM EDT - 1 day ago

ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law

Apr 3, 2025, 11:58 AM EDT - 1 day ago

ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)

Apr 3, 2025, 11:07 AM EDT - 1 day ago

BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm

Apr 3, 2025, 9:37 AM EDT - 1 day ago

FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns

Apr 3, 2025, 8:10 AM EDT - 1 day ago

US FDA declines to approve Aldeyra's eye disease drug

Apr 3, 2025, 8:00 AM EDT - 1 day ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Mar 10, 2025, 7:00 AM EDT - 25 days ago

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Mar 5, 2025, 4:09 PM EST - 4 weeks ago

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA

Feb 4, 2025, 7:00 AM EST - 2 months ago

Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Dec 26, 2024, 4:04 AM EST - 3 months ago

Aldeyra Therapeutics: Key Inflection Point Ahead

Dec 2, 2024, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Nov 18, 2024, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Nov 14, 2024, 7:00 AM EST - 5 months ago

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 14, 2024, 5:31 AM EST - 5 months ago

Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects

ABBV

Oct 31, 2024, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Oct 3, 2024, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Sep 5, 2024, 7:00 AM EDT - 7 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 3:49 PM EDT - 7 months ago

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

ABBV

Aug 8, 2024, 12:30 PM EDT - 8 months ago

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

Aug 8, 2024, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aug 7, 2024, 4:01 PM EDT - 8 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Jun 20, 2024, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Jun 13, 2024, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Jun 12, 2024, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics to Host Investor Roundtable Q&A

Jun 10, 2024, 1:25 PM EDT - 10 months ago

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

May 29, 2024, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Mar 24, 2024, 12:46 AM EDT - 1 year ago

Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

ABBV

Feb 6, 2024, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 28, 2024, 2:56 AM EST - 1 year ago

Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

Jan 4, 2024, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Dec 19, 2023, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Dec 18, 2023, 4:01 PM EST - 1 year ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Nov 27, 2023, 4:07 PM EST - 1 year ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Nov 1, 2023, 7:05 AM EDT - 1 year ago

Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap